![Jeffrey Stein](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Stein
Algemeen Directeur bij CIDARA THERAPEUTICS, INC.
Vermogen: 1 M $ op 31-05-2024
Profiel
Dr. Jeffrey L.
Stein is an Independent Director at IDEAYA Biosciences, Inc. and a President, Chief Executive Officer & Director at Cidara Therapeutics, Inc. He is on the Board of Directors at IDEAYA Biosciences, Inc. and Cidara Therapeutics, Inc. Dr. Stein was previously employed as a Chairman by Antimicrobials Working Group, a Lead Independent Director by Paratek Pharmaceuticals, Inc., a Chairman & President by Antibiotics Working Group, a President, Chief Executive Officer & Director by Trius Therapeutics, Inc., a Venture Partner by Sofinnova Ventures, Inc., a Director-Venture Development by University of California San Diego, a Director, Chief Scientific Officer & Executive VP by Quorex Pharmaceuticals, Inc., a Principal Scientist by Diversa Corp., a Principal Scientist by The Agouron Institute, and an Independent Director by Prevacept Infection Control, Inc. He received his undergraduate degree from The California State University, a graduate degree from The California State University, a doctorate degree from California Institute of Technology and a doctorate degree from the University of California San Diego.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
07-06-2024 | 72 583 ( 1.59% ) | 921 078 $ | 31-05-2024 | |
IDEAYA BIOSCIENCES, INC.
0.01% | 31-05-2024 | 4 281 ( 0.01% ) | 156 471 $ | 31-05-2024 |
Actieve functies van Jeffrey Stein
Bedrijven | Functie | Begin |
---|---|---|
CIDARA THERAPEUTICS, INC. | Algemeen Directeur | 01-01-2014 |
IDEAYA BIOSCIENCES, INC. | Directeur/Bestuurslid | 01-10-2015 |
Eerdere bekende functies van Jeffrey Stein
Bedrijven | Functie | Einde |
---|---|---|
PARATEK PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 21-09-2023 |
Antimicrobials Working Group
![]() Antimicrobials Working Group Miscellaneous Commercial ServicesCommercial Services Antimicrobials Working Group is an American nonprofit company. The firm operates as an association of antimicrobials and diagnostics companies. The company says this about itself: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of thirteen antimicrobials companies: Acurx Pharmaceuticals, Inc., Cidara Therapeutics Inc., CorMedix Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics LLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc. | Voorzitter | 17-01-2019 |
Trius Therapeutics, Inc.
![]() Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Algemeen Directeur | 01-09-2013 |
Antibiotics Working Group | Oprichter | 01-09-2013 |
Sofinnova Investments, Inc.
![]() Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Corporate Officer/Principal | 01-01-2010 |
Opleiding van Jeffrey Stein
The California State University | Undergraduate Degree |
California Institute of Technology | Doctorate Degree |
University of California San Diego | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
CIDARA THERAPEUTICS, INC. | Health Technology |
PARATEK PHARMACEUTICALS, INC. | Health Technology |
IDEAYA BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 8 |
---|---|
Diversa Corp.
![]() Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Diversa searches high and low for DNA. In its quest to develop new enzymes and other active biological compounds, the biotechnology company collects and catalogs the DNA of organisms in diverse environments (from manure piles to tropical islands). A variety of manufacturers license these compounds from the firm to develop or improve their products, which include detergents, oils, animal feeds, and pharmaceuticals. Diversa's products include enzymes for the oil and gas industry | Commercial Services |
Sofinnova Investments, Inc.
![]() Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Quorex Pharmaceuticals, Inc.
![]() Quorex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quorex Pharmaceuticals, Inc. was previously engaged in discovering and developing drugs to address the growing need for new therapies to treat bacterial infections. The company's was purchased by Pfizer Inc in 2005. Quorex was headquartered in Carlsbad, CA. | Health Technology |
Trius Therapeutics, Inc.
![]() Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Prevacept Infection Control, Inc.
![]() Prevacept Infection Control, Inc. Pharmaceuticals: MajorHealth Technology Prevacept Infection Control, Inc. develops and designs pharmaceutical products to eliminate microbial infections. The firm offers B-Lock, an anti-coagulant catheter lock solution with broad spectrum activity against bacterial and fungal microorganisms known to form bio-film structures in indwelling catheters. The company was founded by Krzysztof Appelt and Thomas I. Bradshaw in 2006 and is headquartered in Broomfield, CO. | Health Technology |
Antimicrobials Working Group
![]() Antimicrobials Working Group Miscellaneous Commercial ServicesCommercial Services Antimicrobials Working Group is an American nonprofit company. The firm operates as an association of antimicrobials and diagnostics companies. The company says this about itself: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of thirteen antimicrobials companies: Acurx Pharmaceuticals, Inc., Cidara Therapeutics Inc., CorMedix Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics LLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc. | Commercial Services |
The Agouron Institute | |
Antibiotics Working Group |